IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
IDEXX LABORATORIES INC /DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$555.80−4.56 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $44.08B
- P/E (TTM)
- 39.1
- Dividend yield
- –
Share price
−$79.60 (−12.53%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
IDEXX LABORATORIES INC /DE grew revenue 12.8% to $4.55B over the twelve months to Jun 30, 2026. Operating income rose 16.2% to $1.46B, moving the operating margin from 31.1% to 32.0%. Free cash flow was $1.25B, up 59.9% from a year earlier.
Revenue
$4.55B
+12.8% vs. a year earlier
Operating income
$1.46B
+16.2% vs. a year earlier
Free cash flow
$1.25B
+59.9% vs. a year earlier
EPS, diluted
$14.22
+18.4% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $44.08B
- P/E ratio
- 39.1
- Price to sales
- 9.68
- Price to book
- 27.34
- Dividend yield
- –
- Free cash flow yield
- 2.85%
Fundamentals
- Revenue
- $4.55B
- Net income
- $1.14B
- EPS, diluted
- $14.22
- Free cash flow
- $1.25B
- Book value per share
- $20.33
- Diluted shares
- 79M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$4.55B+12.8% YoY
Gross profit
$2.84B+14.4% YoY
Operating income
$1.46B+16.2% YoY
Net income
$1.14B+15.6% YoY
EPS, diluted
$14.22+18.4% YoY
Free cash flow
$1.25B+59.9% YoY
Reported periodTrailing twelve months